Ondansetron versus Domperidone for the treatment of vomiting in acute gastroenteritis in children

Ondansetron versus Domperidone for the treatment of vomiting in acute gastroenteritis in children

The present study compared the efficacy of Ondansetron versus Domperidone for treating vomiting in acute gastroenteritis (AGE) in children.

The study included 300 children of both genders aged below 12 years, experiencing three or more non-bilious, non-bloody vomiting episodes within 24 hours and with suggestive signs and symptoms of AGE. It equally randomized them into two groups and compared the efficacy of both drugs in terms of the need for 2nd dose within 15 minutes and cessation of vomiting at 6-hour and 24-hour follow-ups.

The study observed-

  • Enrollment of 54.0% male children. 
  • The mean age as 4.7±2.3 years of participants.
  • 18.0% of children in the Ondansetron group required 2nd dose within 15 minutes, while 25.3% of children in the Domperidone group required the 2nd dose. 
  • Cessation of vomiting at 6-hour intervals among 84.0% of children in the Ondansetron group in comparison to 78.7% in the Domperidone group. 
  • 89.4% of children in the Ondansetron group had cessation of vomiting at 24 hours follow-up, while it was only in 80.6% of children in the Domperidone group.

This study regards Ondansetron as superior to Domperidone in having better efficacy aiming cessation of AGE-associated vomiting among children with mild to moderate dehydration.

Ahmad T, Zarafshan U, Sahar B. Comparison of Ondansetron versus Domperidone for treating vomiting in acute gastroenteritis in children at a resource-limited setting of South Punjab, Pakistan. Pak J Med Sci. 2022 Jul-Aug;38(6):1584-1588. doi: 10.12669/pjms.38.6.5532. PMID: 35991241; PMCID: PMC9378405.

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team

pedia1
pedia3
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks